Literature DB >> 14636900

Prognostic value of myocardial viability recognized by low-dose dobutamine echocardiography in chronic ischemic left ventricular dysfunction.

Rosa Sicari1, Eugenio Picano, Lauro Cortigiani, Adrian C Borges, Albert Varga, Caterina Palagi, Riccardo Bigi, Roberta Rossini, Emilio Pasanisi.   

Abstract

This study assesses the prognostic value of myocardial viability recognized as a contractile response to inotropic stimulation in patients with left ventricular (LV) dysfunction in a large-scale prospective, multicenter, observational study. Four hundred twenty-five patients (mean age 61 +/- 10 years) with angiographically proven coronary artery disease, previous (>3 months) myocardial infarction, and severe LV dysfunction (ejection fraction <35%; mean 28 +/- 6%) were enrolled in the study. Each patient underwent low-dose dobutamine echocardiography (up to 10 microg/kg/min). Myocardial viability was identified as a rest-stress variation (Delta) in the wall motion score index (WMSI), in which each segment was scored from 1 = normal to 4 = dyskinetic in a 16-segment model of the left ventricle. Myocardial viability was identified as an improvement of >/=0.40 in WMSI. All patients were followed for a median of 3.1 years. One hundred eighty-eight were revascularized either by coronary artery bypass grafting (n = 118) or coronary angioplasty (n = 70). The only end point analyzed was cardiac death. In the revascularized group, cardiac death occurred in 4 of the 52 patients with and in 37 of the 136 patients without myocardial viability (7.7% vs 27.2%, p <0.003). Kaplan-Meier survival estimates showed a better outcome for those patients with compared to patients without myocardial viability who underwent coronary revascularization (90.1% vs 62%, p <0.0078). Thus, in severe LV ischemic dysfunction, myocardial viability by low-dose dobutamine echocardiography is associated with improved survival in revascularized patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14636900     DOI: 10.1016/j.amjcard.2003.08.004

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Quantity of viable myocardium required to improve survival with revascularization in patients with ischemic cardiomyopathy: A meta-analysis.

Authors:  Yoichi Inaba; Jennifer A Chen; Steven R Bergmann
Journal:  J Nucl Cardiol       Date:  2010-04-09       Impact factor: 5.952

2.  Long term prognostic value of myocardial viability and ischaemia during dobutamine stress echocardiography in patients with ischaemic cardiomyopathy undergoing coronary revascularisation.

Authors:  V Rizzello; D Poldermans; A F L Schinkel; E Biagini; E Boersma; A Elhendy; F B Sozzi; A Maat; F Crea; J R T C Roelandt; J J Bax
Journal:  Heart       Date:  2005-04-06       Impact factor: 5.994

3.  Myocardial viability and survival in ischemic left ventricular dysfunction.

Authors:  Robert O Bonow; Gerald Maurer; Kerry L Lee; Thomas A Holly; Philip F Binkley; Patrice Desvigne-Nickens; Jaroslaw Drozdz; Pedro S Farsky; Arthur M Feldman; Torsten Doenst; Robert E Michler; Daniel S Berman; Jose C Nicolau; Patricia A Pellikka; Krzysztof Wrobel; Nasri Alotti; Federico M Asch; Liliana E Favaloro; Lilin She; Eric J Velazquez; Robert H Jones; Julio A Panza
Journal:  N Engl J Med       Date:  2011-04-04       Impact factor: 91.245

4.  Prognostic value of dobutamine stress echocardiography in diabetic patients.

Authors:  Francesca Innocenti; Chiara Agresti; Caterina Baroncini; Francesca Caldi; Edoardo Mannucci; Matteo Monami; Riccardo Pini
Journal:  Int J Cardiovasc Imaging       Date:  2010-02-14       Impact factor: 2.357

5.  Positron emission tomography for the assessment of myocardial viability: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2005-10-01

Review 6.  The clinical use of stress echocardiography in ischemic heart disease.

Authors:  Rosa Sicari; Lauro Cortigiani
Journal:  Cardiovasc Ultrasound       Date:  2017-03-21       Impact factor: 2.062

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.